Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.
Stijn Van HeesS BourgeoisH Van VlierbergheT SerstéS FrancqueP MichielsenD SprengersH ReynaertJ HenrionS Negrin DastisJ DelwaideL LasserJ DecaesteckerH OrlentF JanssensG RobaeysI ColleP StärkelC MorenoF NevensT Vanwolleghemnull nullPublished in: Alimentary pharmacology & therapeutics (2018)
Treatment withdrawal in Caucasian chronic hepatitis B patients after nucleos(t)ide analogue-induced HBeAg seroconversion results in viral relapses in more than half of patients with potential fatal outcomes. These real-world data further lend support to preferentially continue NA treatment after HBeAg seroconversion until HBsAg loss.
Keyphrases
- hepatitis b virus
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- sars cov
- type diabetes
- combination therapy
- risk assessment
- skeletal muscle
- metabolic syndrome
- oxidative stress
- big data
- insulin resistance
- climate change
- artificial intelligence
- endothelial cells
- weight loss
- drug induced
- data analysis